A cancer vaccine gives 100% efficiency in mouse testing

A study recently published in the Proceedings of the American Academy of Sciences (PNAS) will bring good news to patients, particularly those with melanoma.

Accordingly, scientists at Scripps Research Institute have successfully developed a new vaccine - which when combined with existing therapies - will give 100% treatment efficacy, not only destroy tumors melanoma but also prevent it from recurring.

According to Professor Dale Boger, co-lead researcher with Nobel laureate scientist Bruce Beutler: "This combination therapy provides a complete response - a curative response - in".

The vaccine will give 100% treatment effect, not only kill melanoma but also prevent it from recurring.

100% of the mice lived

New vaccines have been tested on mice. In particular, the scientists gave 3 different treatment options for 3 groups of rats with melanoma.

All three groups were treated with a cancer immunotherapy called anti-PD-L1 . But the first group will get more vaccines. The second group was vaccinated with a molecule called Diprovocim . The third group was vaccinated with an adjuvant.

Diprovocim is an adjuvant that enhances cancer treatment through immune response. This compound is receiving a lot of attention from scientists, because it's easy to synthesize and refine it.

In the Scripps Institute's study, they found that 8 vaccinated mice together with Diprovocim and anti-PD-L1 therapy had a 100% survival rate in 54 days.

Meanwhile, mice vaccinated with anti-PD-L1 all died. The third group of mice that received anti-PD-L1, vaccinated with dozens of them only achieved 25% survival.

"It is interesting to see that this vaccine works simultaneously with anti-PD-L1 cancer immunotherapy , " Professor Boger said.

Diprovocim is an adjuvant that enhances cancer treatment through immune response.

The vaccine also prevents cancer from recurring

However, this is not the only reason researchers are excited. In fact, the test vaccine also has another positive effect - specifically, it protects the mice 'bodies and prevents cancer from recurring.

"Just like a vaccine can train the body to fight outside pathogens, this vaccine trains the immune system to fight tumors back," Professor Boger said.

Scientists discovered, when they tried to activate new melanoma in mice in the second test group, "it was not successful," Professor Boger said. "The mice were vaccinated against it," he explained.

Subsequent experiments have revealed the excellent mechanism behind combination therapy. The researchers determined that Diprovocim increased the immune response by "promoting" the immune system that produces white blood cells to penetrate the tumor. The white blood cells were then able to attack and eliminate cancer.

Professor Boger and his team also noted that vaccines in combination with Diprovocim can be distributed quite easily, because they do not need to be injected directly into cancer tumors to be effective.

Instead, the patient can be intramuscularly as usual and only need 2 injections 7 days apart.

In the coming period, researchers will continue to pre-test this new vaccine, and test its effectiveness when combined with other cancer treatments.